安进Amgen Inc. (AMGN) 2006年年度报告「NASDAQ」.pdf

1、Amgen 2006 Annual ReportOur Promise 2007 Amgen Inc.All rights reserved.MC36222 660M/3-07“When I make controlling my disease a priority,I can keep my commitments to my family and my business.”*Defined as the cumulative number of years of treatment for all ENBREL patients,calculated by multiplying the

2、 number of patients on ENBREL by their individual times on therapy.Joe Carlin of Cary,North Carolina,takes Enbrel(etanercept)to help control his severe plaque psoriasis.ENBREL has made a difference in the lives of people coping with moderate-to-severe rheumatoid arthritis,moderate-to-severe juvenile

3、 rheumatoid arthritis,psoriatic arthritis,ankylosing spondylitis and moderate-to-severe plaque psoriasis.In 2006,Amgen observed a remarkable milestone:one million patient-years of experience*with ENBREL.Amgen 2006 Annual Report 2“We tackle difficult medical and scientific challenges because we are c

4、ommitted to making a dramatic difference for patients.”Dear Stockholders,I am pleased to report that Amgen delivered excellent performance in 2006.We grew revenues and adjusted earnings per share*by 15 and 22 percent,respectively,while increasing our investment in research and development by nearly

5、40 percent to$3.2 billion.*This level of R&D investment is necessary to deliver on the promise of our pipeline,and we are already seeing early returns.It felt good to see our first cancer therapeutic reaching patients.We received U.S.approval for Vectibix to treat metastatic colorectal cancer in pat

6、ients whose disease has progressed after standard chemotherapy.For these gravely ill patients who have few treatment choices left,Vectibix offers a new option and hope for more time.Oncologists acceptance of Vectibixso far has exceeded our expectations,which encourages us as we work to bring this im